First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
Investment to expand manufacturing and global medicine supply capacity
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Marks first international filing for Evofem’s single-dose oral treatment
Subscribe To Our Newsletter & Stay Updated
